Pyrimethamine Inhibits Cell Growth by Inducing Cell Senescence and Boosting CD8 T-cell Mediated Cytotoxicity in Colorectal Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Mar 9

PMID 35262820

Authors

Haiyan Dong

Limei Hu

Weiqian Li

Mengchen Shi

Lingyuan He

Chen Wang

Yijia Hu

Huihui Wang

Chuangyu Wen

Huanliang Liu

Xiangling Yang

Affiliations

Soon will be listed here.

Abstract

Background: The emergence of nonresponse or resistance to traditional chemotherapeutic agents is one of the main challenges of colorectal cancer (CRC) therapies. Thus, novel therapeutic drugs that can improve the clinical outcomes of CRC patients are urgently needed. The purpose of this study was to investigate the effects and mechanisms of pyrimethamine in CRC.

Methods And Results: In this study, we assessed the role of pyrimethamine on CRC cell growth by cell counting kit-8 and colony formation assays. Cell cycle distribution and cellular senescence were determined by flow cytometry and senescence-associated β-galactosidase staining respectively. RNA-seq analysis and western blotting were used to investigate the potential pathways of pyrimethamine in CRC development. Moreover, animal experiments were performed to evaluate the effect of pyrimethamine in vivo. Our results demonstrated that pyrimethamine could inhibit cell growth by inducing S phase arrest followed by cellular senescence in CRC cells, and the p38MAPK-p53 axis was probably involved in that effect. In addition, pyrimethamine could also boost CD8 T-cell mediated cytotoxicity and exert antitumor activity in vivo.

Conclusion: These results indicated that pyrimethamine may be a promising candidate agent for CRC treatment.

Citing Articles

Comprehensive analysis of prognostic and immunological role of basement membrane-related genes in soft tissue sarcoma.

Nie G, Liu C, Tian Z Immun Inflamm Dis. 2024; 12(10):e70037.

PMID: 39392257 PMC: 11467964. DOI: 10.1002/iid3.70037.

Pyrimethamine reduced tumour growth in pre-clinical cancer models: a systematic review to identify potential pre-clinical studies for subsequent human clinical trials.

Manoharan S, Ying Ying L Biol Methods Protoc. 2024; 9(1):bpae021.

PMID: 38618181 PMC: 11014785. DOI: 10.1093/biomethods/bpae021.

Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.

Li X, Yin S, Chen L, Tulamaiti A, Xiao S, Zhang X BMC Cancer. 2024; 24(1):116.

PMID: 38262966 PMC: 10804632. DOI: 10.1186/s12885-024-11885-8.

Caffeic acid phenethyl ester: Unveiling its potential as a potent apoptosis inducer for combating hypopharyngeal squamous cell carcinoma.

Kim H, Ahn M, Shin J, Choi S, Yu H, Cho S Oncol Rep. 2023; 51(2).

PMID: 38099422 PMC: 10777462. DOI: 10.3892/or.2023.8680.

Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma.

Knapp K, Verchio V, Coburn-Flynn O, Li Y, Xiong Z, Morrison J Biochem Pharmacol. 2023; 214:115639.

PMID: 37290594 PMC: 10528900. DOI: 10.1016/j.bcp.2023.115639.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Van der Jeught K, Xu H, Li Y, Lu X, Ji G . Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018; 24(34):3834-3848. PMC: 6141340. DOI: 10.3748/wjg.v24.i34.3834. View

Khan M, Saadalla A, Ewida A, Al-Katranji K, Al-Saoudi G, Giaccone Z . The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2017; 67(1):13-23. PMC: 5783191. DOI: 10.1007/s00262-017-2057-0. View

Liu Y, Zhou H, Yi T, Wang H . Pyrimethamine exerts significant antitumor effects on human ovarian cancer cells both in vitro and in vivo. Anticancer Drugs. 2019; 30(6):571-578. DOI: 10.1097/CAD.0000000000000740. View

Liu H, Qin Y, Zhai D, Zhang Q, Gu J, Tang Y . Antimalarial Drug Pyrimethamine Plays a Dual Role in Antitumor Proliferation and Metastasis through Targeting DHFR and TP. Mol Cancer Ther. 2019; 18(3):541-555. DOI: 10.1158/1535-7163.MCT-18-0936. View

Zhou X, Zhang J, Hu X, He P, Guo J, Li J . Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway. Front Pharmacol. 2020; 11:758. PMC: 7261869. DOI: 10.3389/fphar.2020.00758. View

Jung Y, Kim C, Ha I, Lee S, Lee J, Um J . Pyrimethamine Modulates Interplay between Apoptosis and Autophagy in Chronic Myelogenous Leukemia Cells. Int J Mol Sci. 2021; 22(15). PMC: 8347135. DOI: 10.3390/ijms22158147. View

Brown J, Walker S, Heppler L, Tyekucheva S, Nelson E, Klitgaard J . Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2020; 96(4):E95-E98. PMC: 7954938. DOI: 10.1002/ajh.26084. View

Tai H, Wang Z, Gong H, Han X, Zhou J, Wang X . Autophagy impairment with lysosomal and mitochondrial dysfunction is an important characteristic of oxidative stress-induced senescence. Autophagy. 2016; 13(1):99-113. PMC: 5240829. DOI: 10.1080/15548627.2016.1247143. View

10.

Birch J, Gil J . Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020; 34(23-24):1565-1576. PMC: 7706700. DOI: 10.1101/gad.343129.120. View

11.

Su L, Dong Y, Wang Y, Wang Y, Guan B, Lu Y . Potential role of senescent macrophages in radiation-induced pulmonary fibrosis. Cell Death Dis. 2021; 12(6):527. PMC: 8141056. DOI: 10.1038/s41419-021-03811-8. View

12.

Collado M, Serrano M . Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2009; 10(1):51-7. PMC: 3672965. DOI: 10.1038/nrc2772. View

13.

Karunakaran S, Saeed U, Mishra M, Valli R, Joshi S, Meka D . Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci. 2008; 28(47):12500-9. PMC: 6671725. DOI: 10.1523/JNEUROSCI.4511-08.2008. View

14.

He D, Wu H, Xiang J, Ruan X, Peng P, Ruan Y . Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway. Nat Commun. 2020; 11(1):37. PMC: 6940394. DOI: 10.1038/s41467-019-13911-x. View

15.

Xiang M, Mo L, Zhan Y, Wen H, Zhou H, Miao W . P38-Mediated Cellular Senescence in Conjunctivochalasis Fibroblasts. Invest Ophthalmol Vis Sci. 2019; 60(14):4643-4651. DOI: 10.1167/iovs.19-27617. View

16.

Sun P, Yoshizuka N, New L, Moser B, Li Y, Liao R . PRAK is essential for ras-induced senescence and tumor suppression. Cell. 2007; 128(2):295-308. DOI: 10.1016/j.cell.2006.11.050. View

17.

Sanz G, Singh M, Peuget S, Selivanova G . Inhibition of p53 inhibitors: progress, challenges and perspectives. J Mol Cell Biol. 2019; 11(7):586-599. PMC: 6735775. DOI: 10.1093/jmcb/mjz075. View

18.

Tamer Y, Gaszek I, Abdizadeh H, Batur T, Reynolds K, Atilgan A . High-Order Epistasis in Catalytic Power of Dihydrofolate Reductase Gives Rise to a Rugged Fitness Landscape in the Presence of Trimethoprim Selection. Mol Biol Evol. 2019; 36(7):1533-1550. PMC: 6573477. DOI: 10.1093/molbev/msz086. View

19.

Frede J, Greulich P, Nagy T, Simons B, Jones P . A single dividing cell population with imbalanced fate drives oesophageal tumour growth. Nat Cell Biol. 2016; 18(9):967-78. PMC: 5870829. DOI: 10.1038/ncb3400. View

20.

Tommasino C, Gambardella L, Buoncervello M, Griffin R, Golding B, Alberton M . New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. J Exp Clin Cancer Res. 2016; 35(1):137. PMC: 5013574. DOI: 10.1186/s13046-016-0409-9. View